Abstract: A drug containing a calmodulin inhibitor as an active ingredient is disclosed. This drug is useful in the suppression of neuronal cell death, in particular brain neuronal cell death, due to, for example, cerebral ischemia.Also, a drug containing a compound capable of inhibiting binding of calmodulin to a cytoskeltal protein as an active ingredient and a drug containing a compound suppressing the breakdown of a cytoskeltal protein as an active ingredient are disclosed.These drugs are useful in the treatment and prevention of various diseases in the brain and sequelae thereof as well as in the prevention of relapses of these diseases.

Abstract: A drug containing a calmodulin inhibitor as an active ingredient is disclosed. This drug is useful in the suppression of neuronal cell death, in particular brain neuronal cell death, due to, for example, cerebral ischemia.Also, a drug containing a compound capable of inhibiting binding of calmodulin to a cytoskeltal protein as an active ingredient and a drug containing a compound suppressing the breakdown of a cytoskeltal protein as an active ingredient are disclosed.These drugs are useful in the treatment and prevention of various diseases in the brain and sequelae thereof as well as in the prevention of relapses of these diseases.

Abstract: The present invention relates to a nootropic agent which comprises a derivative of 2-phenyl-3-oxo-2H-1,4-benzothiazine. This nootropic agent is effective for treating diseases accompanied by a lowering of cerebral functions, for instance, cerebral infarction disorders due to ischemia such as transitory cerebral ischemia, brain edema, cerebral disorders due to the after-effect such as cerebral hemorrhage, cerebral disorders due to traumatic injury such as bruise, central nervous degeneration and degenerative diseases such as dementia, mental disorders, neurosis and Alzheimer's diseases.